Background Thyroid nodules are a common finding in Germany. Most are benign; thyroid
cancer is very rare. The challenge for the physician is to diagnose malignant tumors early …

This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four
tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic …

Context: Pazopanib is a small molecule inhibitor of kinases principally including vascular
endothelial growth factor receptors-1,-2, and-3; platelet-derived growth factor receptors-α …

Introduction Few studies have focused on PD-L1 expression in medullary thyroid carcinoma
(MTC). Expressions of PD-1 and PD-L1 and their clinicopathologic and prognostic relevance …

Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy
is surgery, which is the only curative method of the disease. However, in non-operable …

Abstract Approximately 5-10% of all thyroid cancers are medullary thyroid carcinomas
(MTC). MTC is mainly sporadic in nature, but 20-30% of cases are hereditary. Genetic …

Background Medullary thyroid cancer (MTC) is capable of secreting several proteins, such
as calcitonin (Ct), carcinoembryonic antigen (CEA), chromogranin and others. Recently, we …

Medullary thyroid carcinoma (MTC) is highly malignant and quite different from the most
common papillary thyroid carcinoma (PTC). However, most of the ultrasonic evaluation …

Introduction Medullary thyroid carcinoma (MTC) is a neuroendocrine thyroid carcinoma with
parafollicular C cell differentiation. It can occur in either sporadic or hereditary form. Surgery …

Aims Peptide receptor radionuclide therapy (PRRT) has been shown to be useful in
inoperable/metastatic medullary thyroid carcinoma (MTC). However, the role of concomitant …